Clinical Trials in New York

Showing 1881-1900 of 22,668 trials

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

NCT06510361

This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)

LymphomaFollicular LymphomaLymphoma,Non-Hodgkin+1 more

Beth Israel Deaconess Medical Center35 participantsStarted Nov 2024

Stanford, California, United States • Boston, Massachusetts, United States • New York, New York, United States

RECRUITINGPhase 1< 1 mile

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

NCT07470853

HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group. The study consists of 2 parts (Part A: monotherapy and Part B: combination therapy with bevacizumab); each part has 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). Enrollment to Part A (Phase 1a and Phase 1b) will include ovarian and endometrial cancers. Enrollment to Part B (Phase 1a and Phase 1b) will include ovarian cancer only. A subsequent protocol amendment may evaluate additional tumor types.

PROCPlatinum Resistant Ovarian CancerEndometrial Cancer

Whitehawk Therapeutics, Inc.265 participantsStarted Mar 2026

Little Rock, Arkansas, United States • Los Angeles, California, United States • Sarasota, Florida, United States +9 more locations

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Find Trials by Condition in New York

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis

Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)

A Web-Based Tool to Help People With Health Conditions Make Contraceptive Decisions

Terumo Aortic Global Endovascular Registry

Targeting Aging With a Ketone Ester for Function in Frailty

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

Epcoritamab in Previously Treated WM

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease